

21/10/2020

Emyria enters into global partnership with Sapphire Medical Clinics

Highlights:

- Global partnership will leverage Sapphire's clinical and research expertise in the UK, and Emyria's real world evidence data expertise
- Emyria to receive select, deidentified data that will further improve Emyria's Registration and Pharmacovigilance data products
- Sapphire to become preferred clinical service of Emyria's clinical operations for patients in the UK
- Investor webinar to be held on 22 October 2020 11:00am AEDT

Emyria Limited (ASX: EMD) (Emyria or the Company), is pleased to announce that its clinical operations subsidiary, Emerald Clinics, has entered into a global partnership with UK-based Sapphire Medical Clinics ("Sapphire"). The partnership will provide a new source of data to bolster Emyria's growing cannabinoid data platform and allow Emyria to leverage Sapphire's resources and infrastructure in the UK to provide services to UK patients.

Sapphire is led by several prominent clinicians based at leading medical institutions including Imperial College London and King's College. Sapphire's Harley Street clinic in London was the first medicinal cannabis clinic registered by the UK's Care Quality Commission (CQC) in 2019 and is the most recognised medicinal cannabis clinic in the UK.

For the first commercial project, Sapphire will become Emyria's preferred clinical service provider in the UK and Sapphire will provide select, deidentified clinical data based on the use and efficacy of cannabinoid products back to Emyria. This data will be used by Emyria to enhance the value of its leading real-world evidence data platform which generates revenue from clients wishing to track the safety of cannabinoid products ("pharmacovigilance") and also enables unique insights to be generated with respect to new diseases that can be treated with cannabinoids.

The new partnership allows Emyria to fulfil an IPO commitment to support a clinical service in the UK in a capital efficient manner. The partnership also allows Emyria to accelerate performance of the recently announced data agreement with Spectrum UK – the medical arm of the world's largest cannabis company, Canopy Growth. (For more details, please see ASX announcement dated 10-Aug-2020.)

Emyria Managing Director Dr Michael Winlo said: *"We're delighted to be partnering with Sapphire Clinics, the most respected and research-driven medicinal cannabis clinical service the UK. Access to medicinal cannabis in the UK is restricted in similar ways to how access was restricted in Australia a few years ago. We know that regulators in Australia and the UK encourage registration of medicinal cannabis and that this requires high quality clinical evidence."*

*This Agreement is part of an evolving partnership between our two organisations which will allow us to support a clinical service in the UK while also collecting high quality de-identified clinical evidence that can greatly enhance the utility and value of our **Emyria Registration and Emyria Pharmacovigilance** data products, which support drug developers with product registration and monitoring."*



Sapphire Clinics Managing Director Dr Mikael Sodergren said: *“We’re pleased to be working with Emyria, who have already built a robust data registry for medicinal cannabis patients at Emerald Clinics in Australia. This partnership will allow us to define a global standard in real-word evidence data which will provide an invaluable tool for clinicians, regulators and policy makers. Our common goal of advancing personalised medicine in cannabinoid therapy is based on the understanding that data-driven solutions ultimately generate the best outcomes for patients, and this agreement forms a solid foundation to deliver on this global ambition.”*

The UK medicinal cannabis market is predicted to be worth nearly £1bn (AUS\$1.8bn) servicing nearly 340,000 patients. (Source: <https://www.healtheuropa.eu/the-uk-cannabis-report-legal-cannabis-market-to-reach-2-31bn-by-2024/96360/>)

The project with Sapphire is expected to last up to 24 months and provides total consideration to Sapphire of at most £260,000 based on performance milestones. The Sapphire contract allows Emyria to deliver on the recently announced Spectrum UK data contract worth £400,000 to Emyria (see announcement made on 10-Aug-2020) and adds to the recent success in securing further data agreements with Spectrum Therapeutics and Zelira in the last 6 months.

Investor Webinar

Emyria is pleased to invite investors and shareholders to an online Investor Briefing. Chief Executive Officer, Michael Winlo will be providing an update to the market on the recently announced partnership with Sapphire Medical Clinics.

Details of the event are as follows:

Event: Emyria Limited Investor Briefing

Presenters: Michael Winlo, Managing Director

Time: Thursday 22nd October 2020, 11.00 am (AEST)

Where: Zoom Webinar, details to be provided upon registration

To register your interest for the webinar, please click through to the link below:

https://us02web.zoom.us/webinar/register/WN_WTo90yiZrSLt1GBiX3RDA

Participants will be able to submit questions via the Panel throughout the webinar, however, given we are expecting a large number of attendees we encourage shareholders to send through questions via email beforehand to the Company via Investor and Media Relations manager Lexi O’Halloran at lexi@janemorganmanagement.com.au

This announcement has been approved and authorised for release by the board of Emyria Limited.

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800
investors@emyria.com

Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au



About Emyria (www.emyria.com)

Emyria Limited creates data products from robust and ethically sourced Real-World Evidence (RWE) gathered across its specialist clinical network - **Emerald Clinics (www.emeraldclinics.com.au)**. Emyria's data products – **Emyria Registration** and **Emyria Pharmacovigilance** - accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into treatment safety, quality and efficacy. Emyria's data assets are also a source of unique IP for Emyria. In addition, Emyria creates remote patient monitoring technologies, data platforms and care models that further improve the quality of its RWE data assets and insights.

About Sapphire (www.sapphireclinics.com)

Sapphire Medical Clinics is the first medical cannabis clinic registered by the CQC in the UK and offers consultations at Harley Street in London or via telemedicine to patients with a wide range of conditions including paediatric neurology, pain, psychiatry and dermatology. The clinical governance processes at Sapphire are supported by a team of reputable specialists from Imperial College London and King's College, an in-house clinical pharmacist and overseen by Medical Director Dr Michael Platt. Treatment at Sapphire is focused on providing patients with the best available personalised medical care delivered by world renowned specialists. As recommended by NHS England, Sapphire has established a UK patient registry for cannabis-based medicinal products, as part of its Real-World Evidence Platform, which captures essential data including efficacy metrics, adverse events and patient-reported outcome measures using validated methodologies.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.